Issue 6/2018
Content (21 Articles)
Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells
Songlin Liu, Yunhong Tang, Xianrui Yuan, Dun Yuan, Junyu Liu, Buyan Li, Yifeng Li
The molecular mechanism of anticancer action of novel octahydropyrazino[2,1-a:5,4-a′]diisoquinoline derivatives in human gastric cancer cells
Natalia Pawłowska, Agnieszka Gornowicz, Anna Bielawska, Arkadiusz Surażyński, Anna Szymanowska, Robert Czarnomysy, Krzysztof Bielawski
New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations
Elisabetta Bigagli, Cristina Luceri, Maria De Angioletti, Konstantin Chegaev, Mario D’Ambrosio, Chiara Riganti, Elena Gazzano, Simona Saponara, Mariangela Longini, Francesca Luceri, Lorenzo Cinci
Acquired resistance to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in an uncommon G719S EGFR mutation
Atsushi Osoegawa, Takafumi Hashimoto, Yohei Takumi, Miyuki Abe, Tomonori Yamada, Ryoji Kobayashi, Michiyo Miyawaki, Hideya Takeuchi, Tatsuro Okamoto, Kenji Sugio
Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
Aurelia H. M. de Vries Schultink, Robert P. Doornbos, Alexander B. H. Bakker, Kees Bol, Mark Throsby, Cecile Geuijen, David Maussang, Jan H. M. Schellens, Jos H. Beijnen, Alwin D. R. Huitema
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors
Carol Aghajanian, Katherine M. Bell-McGuinn, Howard A. Burris III, Lillian L. Siu, Lee-Ann Stayner, Jennifer J. Wheler, David S. Hong, Carla Kurkjian, Shubham Pant, Ademi Santiago-Walker, Jennifer L. Gauvin, Joyce M. Antal, Joanna B. Opalinska, Shannon R. Morris, Jeffrey R. Infante
A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours
Kyaw L. Aung, Anthony B. El-Khoueiry, Karen Gelmon, Ben Tran, Gaurav Bajaj, Bing He, Tian Chen, Lili Zhu, Sharath Poojary, Shashwati Basak, Zhenhao Qi, Anna Spreafico, Bruce S. Fischer, Jayesh Desai
Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer
R. S. Finn, D. H. Ahn, M. M. Javle, B. R. Tan Jr, C. D. Weekes, J. C. Bendell, A. Patnaik, G. N. Khan, D. Laheru, R. Chavira, J. Christy-Bittel, E. Barrett, M. B. Sawyer, Tanios S. Bekaii-Saab
Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors
Sandrine Hiret, Nicolas Isambert, Carlos Gomez-Roca, Jaafar Bennouna, Mouna Sassi, Hélène de Mont-Serrat, Jean Fan, David Schnell, Jean-Pierre Delord
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors
Michael Carducci, Montaser Shaheen, Ben Markman, Sara Hurvitz, Daruka Mahadevan, Dusan Kotasek, Oscar B. Goodman Jr, Erik Rasmussen, Vincent Chow, Gloria Juan, Gregory R. Friberg, Erick Gamelin, Florian D. Vogl, Jayesh Desai
Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients
Won Young Tak, Baek-Yeol Ryoo, Ho Yeong Lim, Do-Young Kim, Takuji Okusaka, Masafumi Ikeda, Hisashi Hidaka, Jong-Eun Yeon, Eishiro Mizukoshi, Manabu Morimoto, Myung-Ah Lee, Kohichiroh Yasui, Yasunori Kawaguchi, Jeong Heo, Sojiro Morita, Tae-You Kim, Junji Furuse, Kazuhiro Katayama, Takeshi Aramaki, Rina Hara, Takuya Kimura, Osamu Nakamura, Masatoshi Kudo
Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study
Pedro C. Barata, Matthew Cooney, Prateek Mendiratta, Allison Tyler, Robert Dreicer, Jorge A. Garcia
Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases
Naminatsu Takahara, Yousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, Kei Saito, Hiroki Oyama, Sachiko Kanai, Tatsunori Suzuki, Tatsuya Sato, Ryunosuke Hakuta, Kazunaga Ishigaki, Tsuyoshi Takeda, Tomotaka Saito, Suguru Mizuno, Hirofumi Kogure, Minoru Tada, Kazuhiko Koike
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β
Clinton Yam, Rashmi K. Murthy, Gaiane M. Rauch, James L. Murray, Ronald S. Walters, Vicente Valero, Abenaa M. Brewster, Robert C. Bast Jr, Daniel J. Booser, Sharon H. Giordano, Francisco J. Esteva, Wei Yang, Gabriel N. Hortobagyi, Stacy L. Moulder, Banu Arun
Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone
Giandomenico Roviello, Roberto Petrioli, Alberto Bonetta, Raffaele Conca, Maria Grazia Rodriquenz, Michele Aieta
Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma
Chongchong Wang, Juehua Jing, Li Cheng
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer
Navid Sobhani, Daniele Generali, Alberto D’Angelo, Michele Aieta, Giandomenico Roviello
Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction
Kei Kunimasa, Taiki Isei, Harumi Nakamura, Madoka Kimura, Takako Inoue, Motohiro Tamiya, Kazumi Nishino, Toru Kumagai, Shin-ichi Nakatsuka, Hiroko Endo, Masahiro Inoue, Fumio Imamura
Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints
Sarah E. Stump, Young E. Whang, Daniel J. Crona
Design, synthesis and antiproliferative evaluation of novel sulfanilamide-1,2,3-triazole derivatives as tubulin polymerization inhibitors
Shewei Guo, Yingwei Zhen, Mengguo Guo, Longzhou Zhang, Guosheng Zhou
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer
Laura W. Goff, Nilofer S. Azad, Stacey Stein, Jennifer G. Whisenant, Tatsuki Koyama, Ulka Vaishampayan, Howard Hochster, Roisin Connolly, Amy Weise, Patricia M. LoRusso, Safia N. Salaria, Wael El-Rifai, Jordan D. Berlin